Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: teglarinad, teglarinad chloride, daporinad | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 11 Parkinson's papers of 1,929 | 0.67 |
| pathways Reactome | 3 pathways; mostly energy | 0.60 |
No case: the score is under the bar. Receipt 3027
Sealed predictions
- NAMPT in dopamine neurons, braak-0.02 (p 0.964) → +0.82 (p 0.006)receipt 3034
Swarm cases
receipt 3034: NAMPT in dopamine neurons, braak
- power
- full sample +0.44 (p 0.067, n 18), 95% CI -0.03 to +0.75. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.44 (p 0.064, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.43 (p 0.077, n 18). could be the mix.
- skeptic
- leave-one-out range +0.36 to +0.56, sign flips 0; without severely affected donors +0.44 (p 0.067, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NAMPT in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts